Armata Pharmaceuticals (ARMP) Total Liabilities (2013 - 2026)

Armata Pharmaceuticals has disclosed Total Liabilities across 14 years of filings, most recently posting $381.4 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $381.4 million, up 170.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $381.4 million (up 170.42% YoY), and the FY2025 annual result was $295.5 million, up 119.76% from the prior year.
• Total Liabilities came in at $381.4 million for Q1 2026 at Armata Pharmaceuticals, up from $295.5 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $381.4 million in Q1 2026 to a low of $46.2 million in Q1 2022.
• The 5-year median for Total Liabilities is $134.5 million (2024), against an average of $140.8 million.
• Across the five-year window, Total Liabilities declined 20.26% in 2025 and surged 170.42% in 2026, its largest moves.
• Armata Pharmaceuticals' Total Liabilities stood at $59.8 million in 2022, then soared by 118.27% to $130.4 million in 2023, then advanced by 3.09% to $134.5 million in 2024, then jumped by 119.76% to $295.5 million in 2025, then climbed by 29.07% to $381.4 million in 2026.
• The last three Total Liabilities figures came in at $381.4 million (Q1 2026), $295.5 million (Q4 2025), and $185.1 million (Q3 2025), per Business Quant data.